<DOC>
	<DOCNO>NCT01003899</DOCNO>
	<brief_summary>To explore efficacy BIBW 2992 define objective response rate ( Complete Response , Partial Response ) determine Response Evaluation Criteria Solid Tumours [ RECIST ] 1.1 patient advanced ( stage IIIB IV ) adenocarcinoma lung harbour wild-type EGFR .</brief_summary>
	<brief_title>A Phase II Trial Afatinib ( BIBW 2992 ) Third-line Treatment Patients With Stage IIIB/IV Adenocarcinoma Lung Harbouring Wild-type Epidermal Growth Factor ReceptorEGFR</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically confirm stage IIIB/IV adenocarcinoma nonsmall cell lung cancer [ NSCLC ] 2 . Progressive disease follow secondline cytotoxic chemotherapy include least one platinumcontaining regimen 3 . A known wildtype EGFR status 4 . Patients 18 year age old Exclusion criterion : 1 . More two prior cytotoxic chemotherapy treatment regimen relapse metastatic disease 2 . Prior treatment EGFR target small molecule antibody 3 . Radiotherapy surgery within 4 week prior study entry 4 . Active brain metastasis 5 . Known preexist interstitial lung disease 6 . History presence clinically relevant cardiovascular abnormality 7 . Cardiac leave ventricular function rest ejection fraction le 50 % 8 . Absolute neutrophil count [ ANC ] &lt; 1,500/mm3 9 . Platelet count &lt; 100,000/mm3 10 . Creatinine clearance &lt; 60ml/min serum creatinine &gt; 1.5 time upper limit normal 11 . Women childbearing potential , men able father child , unwilling use medically acceptable method contraception trial 12 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>